Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome

To evaluate the effect of RAS-MAPK pathway inhibitor Trametinib on medically refractory chylous effusions in three hospitalized patients with Noonan syndrome.

source https://www.jpeds.com/article/S0022-3476(22)00479-6/fulltext?rss=yes

Comments

Popular posts from this blog

Inside a pediatric clinical rotation #medicalstudent #pediatrics #clinicalrotations

Paper, Not Plastic

University of Medicine and Health Sciences MD Program #medicalstudent #premed #premedlife